Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 7/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | DAPK2 | Q9UIK4 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 2/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 3/20 | 0.35 |
| ▸ | MERTK | Q12866 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071821 | 0.85 | DYRK1A (0.33) | MAPK1DYRK1ADYRK1B | |
| SCHEMBL4064198 | 0.83 | AAK1 (0.40) | STK17BAAK1DYRK1ADYRK1B | |
| SCHEMBL4073666 | 0.81 | MAP4K1 (0.47) | STK17BMAPK1AAK1IDO1TDO2 | |
| SCHEMBL4062958 | 0.80 | PDGFRB (0.53) | KIT | |
| SCHEMBL4069816 | 0.76 | NOS1 (0.46) | STK17BMAPK1AAK1IDO1TDO2 | |
| SCHEMBL4071736 | 0.75 | GAK (0.51) | KIT | |
| SCHEMBL4073899 | 0.72 | DHFR (0.36) | DYRK1ADYRK1B | |
| SCHEMBL5457330 | 0.70 | NOS1 (0.53) | STK17BPDPK1STK17ACFTR | |
| SCHEMBL4106830 | 0.70 | PDPK1 (0.42) | MAPK1SMN1; SMN2PDPK1 | |
| SCHEMBL4113136 | 0.70 | PDPK1 (0.42) | MAPK1SMN1; SMN2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851217-B1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2009-02-11 | — | — | EP | claimed |
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | 4 AZA BIOSCIENCE NV (BE) | 2008-12-18 | — | — | US | claimed |
| EP-1851217-A1 | SUBSTITUTED PYRIDO(2,3-D)PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2007-11-07 | — | — | EP | claimed |
| WO-2006087229-A1 | SUBSTITUTED PYRIDO (2 , 3-D) PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2006-08-24 | — | — | WO | claimed |
| EP-1851217-B1 | SUBSTITUTED PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | 4 AZA IP NV (BE) | 2009-02-11 | — | — | EP | disclosed |
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | 4 AZA BIOSCIENCE NV (BE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312227-A1 | Substituted Pyrido(2,3-D) Pyrimidine Derivatives Useful as Medicines for the Treatment of Autoimmune Disorders | PNPO, TPMT, TNF | STK17B 3963/4885MAPK1 1351/4885SMN1; SMN2 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.